TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15236888

Group type: EXPERIMENTAL
Intervention: Fusafungine plus analgesic (acetaminophen)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Only fusafungine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antibiotic (amoxicillin‐clavulanic acid) plus analgesic (acetaminophen)
Number of subjects: 60
Study: 11943263

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy + Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (never-users of hormone replacement therapy)
Number of subjects: 0
Study: 9810148

Group type: EXPERIMENTAL
Intervention: 15-min nap
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 45-min nap
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-nap
Number of subjects: 30
Study: 8129156

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg and 8 mg (combined analysis)
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg (study 3)
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1637
Study: 2757151

Group type: COMPARATOR
Intervention: Bupivacaine with adrenaline 1:200,000 (pH 3.9) 2 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alkalinised bupivacaine with adrenaline 1:200,000 (pH 6.4) 2 mg/kg
Number of subjects: 24
Study: 769506

Group type: EXPERIMENTAL
Intervention: Amantadine 400 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg daily with pemoline 20 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31310990

Group type: EXPERIMENTAL
Intervention: SIT+WB
Number of subjects: 25

Group type: COMPARATOR
Intervention: SIT
Number of subjects: 25

Group type: COMPARATOR
Intervention: EX+SIT
Number of subjects: 25
Study: 29084960

Group type: EXPERIMENTAL
Intervention: Low-frequency transcranial electrical stimulation (tACS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive controls (endogenous slow-wave activity and rhythmic noise-burst acoustic stimulation)
Number of subjects: 0
Study: 25752972

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 336
Study: 23369360

Group type: EXPERIMENTAL
Intervention: Laser Doppler imaging (LDI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Current diagnostic strategy
Number of subjects: 200
Study: 22022584

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) treatment
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: High dose (40 µg) PTH (1-34)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: PTH treatment
Number of subjects: 944
Study: 19318676

Group type: EXPERIMENTAL
Intervention: T‐cell interferon (IFN)‐gamma release blood assay T‐SPOT.TB (TS.TB)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: QuantiFERON‐TB Gold In‐Tube (QFT‐IT)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Tuberculin skin test (TST)
Number of subjects: 331

Group type: COMPARATOR
Intervention: TST
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: QFT‐IT
Number of subjects: 331
Study: 16954994

Group type: EXPERIMENTAL
Intervention: Drain group (n = 101)
Number of subjects: 198

Group type: COMPARATOR
Intervention: No-drain group (n = 97)
Number of subjects: 198
Study: 16285323

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (previous treatment)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Elimination of topical corticosteroids and gradual reduction of skin-care products
Number of subjects: 23

Group type: COMPARATOR
Intervention: Face-care or eye-care products usage
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Time to healing
Number of subjects: 23

Group type: COMPARATOR
Intervention: History of atopic diseases and reactive prick tests
Number of subjects: 23
Study: 10970915

Group type: COMPARATOR
Intervention: St. John's wort
Number of subjects: 40

Group type: COMPARATOR
Intervention: Kava
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ginkgo biloba
Number of subjects: 40

Group type: COMPARATOR
Intervention: Valerian
Number of subjects: 40
Study: 9486442

Group type: EXPERIMENTAL
Intervention: Reviewed group (n = 42)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Not reviewed group (n = 38)
Number of subjects: 80
Study: 8179563

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 mcg/kg iv)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg im)
Number of subjects: 55
Study: 3953214

Group type: EXPERIMENTAL
Intervention: 2 grams of dicloxacillin as an intravenous infusion at the induction of anaesthesia
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 grams of dicloxacillin as an intravenous infusion 3 hours before surgery
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 grams of dicloxacillin as an intravenous infusion approximately 6 hours before surgery
Number of subjects: 21
Study: 29888581

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (2 Hz/100 Hz, 4‐8 mA) applied to specific acupuncture points, 3 times a week for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (diet control and aerobic exercise, 3 times a week for 12 weeks)
Number of subjects: 58
Study: 28622156

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training of 30 min three to five times per week
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Isometric handgrip training five times weekly (two contractions of 2 min at 30% of maximal power with each arm)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham-handgrip training five times weekly (two contractions of 2 min at 5% of maximal power with each arm)
Number of subjects: 75
Study: 25088860

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP block (30 mL of 0.25% bupivacaine with epinephrine)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided TAP block (30 mL of 0.25% bupivacaine with epinephrine)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Trocar site infiltration of bupivacaine
Number of subjects: 88
Study: 22890495

Group type: EXPERIMENTAL
Intervention: PLP training at high frequency (2.5 Hz)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PLP training at low frequency (0.5 Hz)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional resistance training (0.5 Hz)
Number of subjects: 30
Study: 21143686

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention including a personalized report, booklet on alcohol and aging, drinking diary, advice from the primary care provider, and telephone counseling from a health educator at 2, 4, and 8 weeks.
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention
Number of subjects: 631
Study: 19036425

Group type: EXPERIMENTAL
Intervention: Telcagepant 300 mg
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: Telcagepant 150 mg
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1380
Study: 16416114

Group type: EXPERIMENTAL
Intervention: Cyclosporin-A (group B)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Induction chemotherapy regimen (idarubicin, cytarabine, etoposide) (group A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Induction chemotherapy regimen (group A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 12837566

Group type: EXPERIMENTAL
Intervention: Levetiracetam 500mg bid (increased to a maximum of 1500mg bid)
Number of subjects: 1030
Study: 11094035

Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5 to 50 mg daily)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 261
Study: 8659977

Group type: EXPERIMENTAL
Intervention: Sterile technique
Number of subjects: 156

Group type: COMPARATOR
Intervention: Clean/non-sterile technique
Number of subjects: 156
Study: 1798003

Group type: EXPERIMENTAL
Intervention: lacidipine (4-6 mg once a day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study: 7039160

Group type: EXPERIMENTAL
Intervention: mexiletine (MEX; 400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: mexiletine (MEX; 600 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: mexiletine (MEX; 800 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lorcainide (LOR; 200 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lorcainide (LOR; 300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lorcainide (LOR; 400 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo (PL)
Number of subjects: 12
Study: 31855716

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg) administered into the CPB pump prime
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 30865172

Group type: EXPERIMENTAL
Intervention: Vignettes with both characters identified as Black
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Interracial character vignettes
Number of subjects: 134

Group type: COMPARATOR
Intervention: Vignettes with both characters identified as White
Number of subjects: 134
Study: 29247531

Group type: COMPARATOR
Intervention: Early rehabilitation program only
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EMS add-on therapy
Number of subjects: 80
Study: 25288340

Group type: EXPERIMENTAL
Intervention: ropivacaine + morphine + ketorolac
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: ropivacaine + morphine + ketorolac + methylprednisolone
Number of subjects: 256

Group type: COMPARATOR
Intervention: control (saline solution, epinephrine, and cefazolin)
Number of subjects: 256
Study: 23925619

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy plus naltrexone (100 mg/d)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Prolonged exposure therapy plus placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Supportive counseling plus naltrexone (100 mg/d)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Supportive counseling plus placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/d)
Number of subjects: 165
Study: 21764858

Group type: EXPERIMENTAL
Intervention: Low-fat (LF) diet
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Flaxseed-supplemented (FS) diet
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: FS+LF diet
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control (usual diet)
Number of subjects: 145
Study: 19493392

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 314

Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: ESWL
Number of subjects: 314
Study: 16484702

Group type: EXPERIMENTAL
Intervention: Cisplatin administration at dosages above 60 mg/m2
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cisplatin administration once every 2 weeks
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cisplatin administration
Number of subjects: 328
Study: 15167652

Group type: EXPERIMENTAL
Intervention: Back to Fitness program (exercise program)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Usual general practitioner care (control group)
Number of subjects: 187
Study: 10930920

Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 60
Study: 8102427

Group type: EXPERIMENTAL
Intervention: Azithromycin (single oral dose of 20 mg/kg)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Conventional treatment (6 weeks of topical tetracycline plus erythromycin for severe cases)
Number of subjects: 194
Study: 3524092

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 28970212

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg/week
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 26889632

Group type: EXPERIMENTAL
Intervention: Safinamide 100 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25142571

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Sleep Seminar Education Control (SS)
Number of subjects: 123
Study: 22952383

Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129Xe MR imaging
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hyperpolarized 3He MR imaging
Number of subjects: 18
Study: 20445180

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 3687

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents
Number of subjects: 3687
Study: 19025388

Group type: EXPERIMENTAL
Intervention: Retrograde ureteroscopic lithotripsy using a semirigid ureteroscope (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic ureterolithotomy (Group B)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotripsy (Group C)
Number of subjects: 150
Study: 15706143

Group type: EXPERIMENTAL
Intervention: Uranium intake from drinking water (0.03‐2,775 microg d)
Number of subjects: 205
Study: 12566359

Group type: EXPERIMENTAL
Intervention: Paclitaxel low dose (1.28 microg/mm2)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Paclitaxel high dose (3.10 microg/mm2)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (bare metal stents)
Number of subjects: 81
Study: 10610628

Group type: EXPERIMENTAL
Intervention: Alcoholic chlorhexidine (0.5%)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Aqueous povidone-iodine (10%)
Number of subjects: 403
Study: 8824691

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (1.6 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oral salbutamol (4 mg)
Number of subjects: 7
Study: 1552354

Group type: EXPERIMENTAL
Intervention: Protein intake of 1.0 g.kg‐1.d‐1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Protein intake of 0.8 g.kg‐1.d‐1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Protein intakes of 0.8 and 1.0 g.kg‐1.d‐1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Protein intake of 0.6 g.kg‐1.d‐1
Number of subjects: 13
Study: 2409613

Group type: EXPERIMENTAL
Intervention: Heparin-DHE
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Phenindione
Number of subjects: 644

Group type: COMPARATOR
Intervention: Control
Number of subjects: 644
Study: 30847720

Group type: EXPERIMENTAL
Intervention: Local anaesthesia and conscious sedation (LACS)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Local anaesthesia (LA)
Number of subjects: 149
Study: 28886209

Group type: EXPERIMENTAL
Intervention: Twofold ALA-PDT
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional MAL-PDT
Number of subjects: 162
Study: 27334885

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (a long-acting local anaesthetic)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of 0.25% bupivacaine and methylprednisolone 16 mg per nerve
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 30
Study: 23841532

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5-5 mg
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study: 22717457

Group type: EXPERIMENTAL
Intervention: Atopic keratoconjunctivitis (AKC) patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Obstructive MGD patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 12
Study: 20116804

Group type: EXPERIMENTAL
Intervention: Infants who observed an experimenter perform actions with one or two toys and then were offered a novel toy that was not demonstrated for them.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants who practiced the target actions on the demonstration trials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants who saw demonstrations with only a single exemplar toy.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants who had not performed the actions with the demonstration toys themselves.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants who saw actions that produced no effects on the demonstrations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants who saw different looking toys.
Number of subjects: 0
Study: 18554657

Group type: EXPERIMENTAL
Intervention: Tubeless percutaneous nephrolithotomy (group 2 treatment)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nephrostomy placement (group 1 control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 16000127

Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy
Number of subjects: 132
Study: 12423707

Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTCA)
Number of subjects: 1238
Study: 10877459

Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg inhaled bd for 5 days
Number of subjects: 2235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2235
Study: 8596268

Group type: EXPERIMENTAL
Intervention: Haloperidol (4 mg by mouth)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1370264

Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (3 to 10 micrograms/kg/day, daily subcutaneous injection for 4 months after 1 month of dose titration)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Observation for 4 months followed by r‐metHuG‐CSF treatment
Number of subjects: 41
Study: 6476812

Group type: EXPERIMENTAL
Intervention: Rimantadine hydrochloride (RH) 100 mg twice a day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 29389150

Group type: EXPERIMENTAL
Intervention: Family-focused therapy for CHR for psychosis
Number of subjects: 102

Group type: COMPARATOR
Intervention: Family-focused therapy for CHR for bipolar disorder
Number of subjects: 102
Study: 26643404

Group type: EXPERIMENTAL
Intervention: Bosentan (125 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 16
Study: 25029046

Group type: EXPERIMENTAL
Intervention: Auriculotherapy with no protocol
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Auriculotherapy with protocol
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 175
Study: 23068088

Group type: COMPARATOR
Intervention: No supplementation unless symptomatic (for PTH ≥ 10)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (for PTH <10)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Calcium and calcitriol supplementation (for PTH <10)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: No supplementation (for PTH <10)
Number of subjects: 143
Study: 20394250

Group type: EXPERIMENTAL
Intervention: 2 ml of 2% lidocaine (40 mg) and 0.5 mL atracurium (5 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 2 ml of 2% lidocaine (40 mg) and 0.5 ml 0.9% NaCl (Control)
Number of subjects: 64
Study: 17084621

Group type: EXPERIMENTAL
Intervention: Sequential chemo-radiotherapy (Gemcitabine 1250mg/m² days 1, 8; Cisplatin 75mg/m² day 2)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Concurrent chemo-radiotherapy (daily low-dose Cisplatin 6mg/m² with radiotherapy 66Gy)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Concurrent chemo-radiotherapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Sequential chemo-radiotherapy
Number of subjects: 158
Study: 15608039

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture analgesia (EA)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional analgesia (CA)
Number of subjects: 160
Study: 12358867

Group type: EXPERIMENTAL
Intervention: Structured, problem‐orientated, time‐limited psychotherapeutic intervention (IG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Routine diabetes care (CG)
Number of subjects: 46
Study: 10430432

Group type: EXPERIMENTAL
Intervention: Lexipafant 500 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7490991

Group type: EXPERIMENTAL
Intervention: Short problem‐based training course in pharmacotherapy using a WHO manual on rational prescribing.
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 219
Study: 2098857

Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Etomidate (0.3 mg/kg)
Number of subjects: 40
Study: 7042362

Group type: EXPERIMENTAL
Intervention: Indoprofen 600 mg/day
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Indoprofen 1000 mg/day
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: ASA 3600 mg/day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 31189035

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 736

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 736
Study: 28207530

Group type: EXPERIMENTAL
Intervention: Midazolam 0.02 mg/kg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 82
Study: 26559319

Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simulated MWM (sham)
Number of subjects: 40
Study: 24038797

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) for 8 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 101
Study: 21910701

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123